Abstract
The V beta 8.3-specific superantigenic lectin Urtica dioica agglutinin (UDA) was used to delete the V beta 8.3+ T cells in MRL lpr/lpr mice. In contrast to the systemic lupus erythematosus-like pathology which progresses with age in the phosphate-buffered saline-injected MRL lpr/lpr controls, UDA-treated animals did not develop overt clinical signs of lupus and nephritis. The pathogenic T cell clones thus reside within the V beta 8.3+ T cell population, which includes an expanded T cell clone described previously. Finally, UDA alters the production of autoantibodies in a sex-dependent manner.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Epitopes / administration & dosage
-
Epitopes / therapeutic use
-
Female
-
Injections, Intravenous
-
Lectins / administration & dosage
-
Lectins / therapeutic use*
-
Lupus Erythematosus, Systemic / immunology
-
Lupus Erythematosus, Systemic / pathology*
-
Lupus Erythematosus, Systemic / prevention & control*
-
Male
-
Mice
-
Mice, Mutant Strains
-
Plant Lectins*
-
Receptors, Antigen, T-Cell, alpha-beta / immunology*
-
Superantigens / administration & dosage
-
Superantigens / therapeutic use*
Substances
-
Epitopes
-
Lectins
-
Plant Lectins
-
Receptors, Antigen, T-Cell, alpha-beta
-
Superantigens
-
stinging nettle lectin